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1. INTRODUCTION {#brb31036-sec-0005}
===============

Impulse control disorder (ICD) generally refers to four major disorders: pathological gambling, compulsive sexual behavior, compulsive buying, and binge eating. Impulse control behaviors (ICBs) consist of ICDs and a number of closely related behaviors, including punding, hobbyism, walkabout, and dopamine dysregulation syndrome (DDS) (Zurowski & O\'Brien, [2015](#brb31036-bib-0056){ref-type="ref"}). The prevalence of ICD or ICB has been reported to be 3.5%--58.3% in patients with Parkinson\'s disease (PD) (Antonini et al., [2017](#brb31036-bib-0001){ref-type="ref"}; Callesen, Weintraub, Damholdt, & Moller, [2014](#brb31036-bib-0006){ref-type="ref"}; Erga, Alves, Larsen, Tysnes, & Pedersen, [2017](#brb31036-bib-0011){ref-type="ref"}; Fan, Ding, Ma, & Chan, [2009](#brb31036-bib-0013){ref-type="ref"}; Rodriguez‐Violante, Gonzalez‐Latapi, Cervantes‐Arriaga, Camacho‐Ordonez, & Weintraub, [2014](#brb31036-bib-0034){ref-type="ref"}; Vela et al., [2016](#brb31036-bib-0044){ref-type="ref"}). ICB is an important nonmotor complication in patients with PD because it is associated with functional impairment, decreased quality of life and increased caregiver burden (Weintraub, David, Evans, Grant, & Stacy, [2015](#brb31036-bib-0049){ref-type="ref"}). Previous studies have shown that dopamine agonist (DA) use is the most consistent predictor of ICB (Weintraub, Koester, et al., [2010](#brb31036-bib-0051){ref-type="ref"}; Weintraub, et al., [2015](#brb31036-bib-0049){ref-type="ref"}; Zurowski & O\'Brien, [2015](#brb31036-bib-0056){ref-type="ref"}). ICB is also independently associated with younger age, younger age at PD onset, previous ICB history, family history of gambling disorders, concurrent cigarette smoking, unmarried status, depression, anxiety, alcohol use, novelty‐seeking traits, higher DA dosage, combination DA and L‐DOPA therapy, and higher L‐dopa doses (Weintraub, Koester, et al., [2010](#brb31036-bib-0051){ref-type="ref"}; Weintraub, et al., [2015](#brb31036-bib-0049){ref-type="ref"}; Zurowski & O\'Brien, [2015](#brb31036-bib-0056){ref-type="ref"}). There are conflicting data about whether amantadine and deep brain stimulation may be a treatment or a potential risk factor for ICB (Cera et al., [2014](#brb31036-bib-0007){ref-type="ref"}; Weintraub, Sohr, et al., [2010](#brb31036-bib-0054){ref-type="ref"}; Weintraub et al., [2015](#brb31036-bib-0049){ref-type="ref"}; Zurowski & O\'Brien, [2015](#brb31036-bib-0056){ref-type="ref"}).

A number of cross‐sectional studies of ICB in PD have been conducted, but longitudinal assessments have been less reported (Antonini et al., [2017](#brb31036-bib-0001){ref-type="ref"}; Avila, Cardona, Martin‐Baranera, Bello, & Sastre, [2011](#brb31036-bib-0003){ref-type="ref"}; Bastiaens, Dorfman, Christos, & Nirenberg, [2013](#brb31036-bib-0004){ref-type="ref"}; Mamikonyan et al., [2008](#brb31036-bib-0027){ref-type="ref"}; Siri et al., [2015](#brb31036-bib-0038){ref-type="ref"}; Smith, Xie, & Weintraub, [2016](#brb31036-bib-0039){ref-type="ref"}; Sohtaoglu, Demiray, Kenangil, Ozekmekci, & Erginoz, [2010](#brb31036-bib-0040){ref-type="ref"}) and little is known about the course or change in ICB according to the type of medication. ICBs are not permanent symptoms and can go into remission (Avila et al., [2011](#brb31036-bib-0003){ref-type="ref"}; Mamikonyan et al., [2008](#brb31036-bib-0027){ref-type="ref"}; Siri et al., [2015](#brb31036-bib-0038){ref-type="ref"}; Sohtaoglu et al., [2010](#brb31036-bib-0040){ref-type="ref"}). In previous studies, the ICB remission ratio in PD was reported to be 40% during 3.5 years of follow‐up period (Siri et al., [2015](#brb31036-bib-0038){ref-type="ref"}) to 73.3% over 29.2 months (Mamikonyan et al., [2008](#brb31036-bib-0027){ref-type="ref"}). The factors associated with ICB remission were reduction in DA use (Avila et al., [2011](#brb31036-bib-0003){ref-type="ref"}), lower DA dosage (Mamikonyan et al., [2008](#brb31036-bib-0027){ref-type="ref"}; Sohtaoglu et al., [2010](#brb31036-bib-0040){ref-type="ref"}), and better working memory performance (Bastiaens et al., [2013](#brb31036-bib-0004){ref-type="ref"}). However, the reduction or discontinuation of DA may induce DA withdrawal symptoms and worsen motor symptoms, meaning that formulating a treatment strategy for ICB is problematic (Weintraub et al., [2015](#brb31036-bib-0049){ref-type="ref"}; Zurowski & O\'Brien, [2015](#brb31036-bib-0056){ref-type="ref"}). Furthermore, little is known about the factors regarding ICB remission and persistence. Therefore, we conducted a longitudinal case--control study of the remission, persistence, and development of ICB and its associated factors, particularly in relation to medication in patients with PD.

2. MATERIAL AND METHODS {#brb31036-sec-0006}
=======================

2.1. Study design and participants {#brb31036-sec-0007}
----------------------------------

We retrospectively investigated sequential outpatients with PD using a computerized medical database of the movement disorder clinic at Aomori Prefectural Central Hospital, Aomori, which is a regional tertiary center located in northern territory of Japan. The recruitment period was from April 2014 to May 2015. The inclusion criteria were as follows: patients diagnosed with PD (hereinafter referred to as PD patients) according to the UK Brain Bank criteria (Hughes, Daniel, Kilford, & Lees, [1992](#brb31036-bib-0017){ref-type="ref"}) and patients who could be followed up over a 2‐year observational period. The exclusion criteria were as follows: patients with dementia, patients with any missing data, and the "exclusion criteria for PD" which was described in the UK Brain Bank criteria (Hughes et al., [1992](#brb31036-bib-0017){ref-type="ref"}). Dementia was diagnosed if the patient had a Mini--Mental State Examination MMSE score ≦23 (Holsinger, Deveau, Boustani, & Williams, [2007](#brb31036-bib-0016){ref-type="ref"}) at baseline.

The Questionnaire for Impulsive--Compulsive Disorders in Parkinson\'s disease (QUIP) is a self‐administered questionnaire specifically assessing ICB (pathological gambling, sexual behavior, compulsive buying, binge eating, punding, hobbyism, walkabout, and DDS) in PD (Weintraub et al., [2009](#brb31036-bib-0050){ref-type="ref"}). All patients completed a validated Japanese version of the QUIP short form (Tanaka, Wada‐Isoe, Nakashita, Yamamoto, & Nakashima, [2013](#brb31036-bib-0041){ref-type="ref"}) at each visit because we administer this as a standard practice at our institution. When the patient had at least one "yes" response, we interviewed them and their caregivers to confirm whether those behaviors were ICB by the established diagnostic criteria (Voon & Fox, [2007](#brb31036-bib-0046){ref-type="ref"}). We defined ICB as positive in cases with both at least one "yes" in QUIP and fulfilling the diagnostic criteria. When the patient answered "no" to ICB symptoms, we confirmed this by self‐report and by asking their caregivers. We defined ICB as being in remission when patients who had ICB at baseline screened negative for any QUIP at the 2‐year follow‐up. We then classified patients into "ICB persister" (ICB at baseline and follow‐up), "ICB remitter" (ICB at baseline but not follow‐up), and "ICB developer" (no ICB at baseline, but ICB at follow‐up) groups. The following assessments were also performed by the movement disorder specialists at each visit: Hoehn and Yahr scale, United Parkinson\'s Disease Rating Scale, MMSE, olfactory dysfunction and dyskinesia. The presence of olfactory dysfunction was assessed only by interview, not by specific odor tests. The presence of dyskinesia was evaluated with history taking and neurological examination. The types and doses of PD medication prior to the visit were recorded at each visit. L‐DOPA equivalent dose (LED) was calculated using a formula reported by Tomlinson et al. ([2010](#brb31036-bib-0042){ref-type="ref"}). The differences in medication dosage between baseline and 2‐year follow‐up are expressed as ΔLED.

This study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of Aomori Prefectural Central Hospital. Written informed consent for participation in the study was not obtained from the patients because the study was retrospective in nature and the data were analyzed anonymously.

2.2. Statistical analysis {#brb31036-sec-0008}
-------------------------

Demographic data were compared between ICB‐positive and ICB‐negative patients using chi‐square tests for categorical variables and Mann--Whitney *U* tests for continuous variables. Multivariate analysis was not able to be performed because of the small sample size. Statistical analysis was performed using the software program Excel‐toukei (BellCurve; Tokyo, Japan). Data are shown as median values and interquartile ratios. All analyses were exploratory in nature, and *p* values of \<0.01 were defined as significant to minimize the effects from multiple comparisons based on the concept of Bonferroni correction.

3. RESULTS {#brb31036-sec-0009}
==========

Two hundred and forty‐five PD patients visited our PD clinic during the study period. Of these, 148 patients were followed up for 2 years, seven patients were excluded by the exclusion criteria, and 141 patients were enrolled in the study (Figure [1](#brb31036-fig-0001){ref-type="fig"}).

![Study flow. Two hundred and forty‐five patients visited our movement disorder clinic during recruitment period. One hundred and forty‐eight patients were followed up over a 2‐year observational period. Seven patients were excluded by the exclusion criteria. Finally, 141 patients were analyzed. At baseline, 30 patients had impulse control behaviors (ICB) and 111 patients did not have ICB. At the 2‐year follow‐up of the patients with ICB at baseline (*n* = 30), 12 had persistent ICB while 18 had ICB in remission, and of the patients without ICB at baseline (*n* = 111), 14 developed ICB while 97 patients did not develop ICB](BRB3-8-e01036-g001){#brb31036-fig-0001}

3.1. Baseline demographic data {#brb31036-sec-0010}
------------------------------

The patients\' demographic characteristics at baseline are presented in Table [1](#brb31036-tbl-0001){ref-type="table"}. Overall, 21.3% (30/141) of patients had at least one ICB. L‐DOPA was used by 95.0% (134/141), and DA was used by 46.8% (66/141) in our cohorts. Pergolide use was higher in patients with ICB than those without ICB (23% vs. 5.4%, *p* = 0.003). No other characteristics were significantly different. The prevalences of QUIP items at baseline are presented in Table [2](#brb31036-tbl-0002){ref-type="table"}. Hobbyism was the most frequent ICB symptom (43.3%), and no one had any symptoms of walkabout. The numbers of QUIP module positivity were as follows: single, 53.3% and multiple, 46.7% (Table [2](#brb31036-tbl-0002){ref-type="table"}).

###### 

Patient demographics at baseline

                                              ICB+, *n* = 30    ICB−, *n* = 111   *p*
  ------------------------------------------- ----------------- ----------------- -----------
  Sex, male (%)                               14 (46.7)         37 (33.3)         0.178
  Age, median (IQR)                           68 (63.3--75.8)   71 (64.5--75)     0.542
  Onset age, year, median (IQR)               62 (53.5--68.8)   65 (59--70)       0.25
  Disease duration, year, median (IQR)        6.5 (10--26)      5 (3--9)          0.091
  Olfactory dysfunction, *n* (%)              17 (56.7)         40 (36)           0.041
  Dyskinesia, *n* (%)                         8 (26.7)          23 (20.7)         0.485
  Deep brain stimulation treatment, *n* (%)   0 (0)             3 (2.7)           0.363
  MMSE score, median (IQR)                    28 (25--29)       27 (25--29.5)     0.897
  HY stage, median (IQR)                      2.5 (2--3)        2 (2--3)          0.313
  UPDRS part III, median (IQR)                14 (10--26)       19 (12--28.5)     0.174
  Medication                                                                      
  L‐DOPA use, *n* (%)                         28 (93.3)         106 (95.5)        0.629
  L‐DOPA use, monotherapy, *n* (%)            8 (26.7)          31 (27.9)         0.891
  DA use, *n* (%)                             20 (66.7)         46 (41.4)         0.014
  Pramipexole IR use, *n* (%)                 4 (13.3)          5 (4.5)           0.079
  Pramipexole ER use, *n* (%)                 4 (13.3)          19 (17.1)         0.619
  Ropinirole CR use, *n* (%)                  3 (10)            17 (15.3)         0.459
  Rotigotine use, *n* (%)                     0 (0)             7 (6.3)           0.158
  Pergolide use, *n* (%)                      7 (23)            6 (5.4)           **0.003**
  Amantadine use, *n* (%)                     12 (40)           23 (20.7)         0.033
  Selegiline use, *n* (%)                     6 (20)            16 (14.4)         0.454
  Entacapone use, *n* (%)                     5 (16.7)          13 (11.7)         0.471
  Zonisamide use, *n* (%)                     9 (30)            19 (17.1)         0.117
  Istradefylline use, *n* (%)                 1 (3.3)           6 (5.4)           0.643
  LED‐total mg, median (IQR)                  657 (450--845)    530 (378--782)    0.182
  LED‐L‐DOPA mg, median (IQR)                 450 (300--600)    400 (300--525)    0.329
  LED‐DA mg, median (IQR)                     125 (0--197)      38 (0--240)       0.815
  LED‐other PD drugs mg, median (IQR)         12.5 (0--150)     0 (0--100)        0.110

CR: controlled release; DA: dopamine agonist; ER: extended release; HY: Hoehn and Yahr scale; ICB: impulse control behavior; IQR: interquartile range; IR: immediate release; LED: L‐DOPA equivalent dose; MMSE: Mini--Mental State Examination; UPDRS: United Parkinson\'s Disease Rating Scale.

Bold indicates *p* \<0.01.
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###### 

Types and numbers of ICB

                                    Baseline    2‐year follow‐up   *p* (ICB persister vs. ICB developer)   
  --------------------------------- ----------- ------------------ --------------------------------------- -------
  ICB subtypes, *n* (%)                                                                                    
  Pathological gambling             7 (23.3)    3 (25)             1 (7.1)                                 0.453
  Compulsive sexual behavior        5 (16.7)    2 (16.7)           1 (7.1)                                 0.750
  Compulsive buying                 6 (20)      4 (33.3)           2 (14.3)                                0.517
  Binge eating                      6 (20)      3 (16.7)           4 (28.6)                                0.979
  Punding                           6 (20)      6 (50)             5 (35.7)                                0.763
  Hobbyism                          13 (43.3)   5 (41.7)           6 (42.9)                                0.998
  Walkabout                         0           0                  0                                       
  Dopamine dysregulation syndrome   8 (26.7)    5 (41.7)           2 (14.3)                                0.292
  Number of QUIP module, *n* (%)                                                                           
  Single                            16 (53.3)   6 (50)             8 (57.1)                                0.934
  Multiple                          14 (46.7)   6 (50)             6 (42.9)                                0.936

ICB: impulse control behavior; QUIP: Questionnaire for Impulsive--Compulsive in Parkinson\'s Disease.
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3.2. Two‐year follow‐up {#brb31036-sec-0011}
-----------------------

After 2 years of follow‐up, 60% (18/30) of patients with ICB at baseline had ICB in remission, 40% (12/30) of those had persistent ICB, and 12.6% (14/111) had developed ICB. At the 2‐year follow‐up, the prevalence of ICB was significantly higher in patients with ICB at baseline than those without ICB at the baseline (*p* \< 0.001). No patients had initiated DBS therapy during the 2 years.

The characteristics of patients at 2‐year follow‐up are shown in Table [3](#brb31036-tbl-0003){ref-type="table"}. Patients identified as "ICB persisters" were significantly younger (*p* = 0.005) and had more pergolide use (*p* = 0.005) than "ICB remitter" patients. No other variables were statistically significantly different between these groups.

###### 

Characteristics of patients at the 2‐year follow‐up

                                          ICB+ at baseline       ICB− at baseline                                                     
  --------------------------------------- ---------------------- -------------------- ----------- ------------------ ---------------- -------------
  Demographics                                                                                                                        
  Sex, male (%)                           5 (41.7)               9 (50)               0.654       9 (64.3)           28 (28.9)        **0.009**
  Age, median (IQR)                       66 (56.8--69.8)        77 (69--80.8)        **0.005**   73.5 (58.8--75)    74 (67--78)      0.221
  Onset age, year, median (IQR)           57 (19--62)            66.5 (57.3--69)      0.037       60 (50.3--65.5)    66 (59--70)      0.057
  Disease duration, year, median (IQR)    7 (5.8--9)             11 (7.3--12)         0.065       8.5 (7.3--11)      8 (5--11)        0.416
  Olfactory dysfunction, *n* (%)          7 (58.3)               10 (55.6)            0.880       5 (35.7)           35 (36.1)        0.979
  RBD, *n* (%)                            6 (50)                 7 (38.9)             0.547       7 (50)             40 (41.2)        0.535
  Dyskinesia, *n* (%)                     4 (33.3)               6 (33.3)             1           7 (50)             17 (17.5)        **0.006**
  MMSE score, median (IQR)                28.5 (27.8--30)        25 (22.3--29.3)      0.075       26 (22.3--28.8)    28 (25--30)      0.184
  HY, median (IQR)                        2.3 (2--3)             3 (2.5--3.5)         0.052       2 (2--3)           2.5 (2--3)       0.512
  UPDRS part 3, median (IQR)              14 (8.5--22)           24.5 (16.3--29)      0.082       16 (10--21.3)      19 (11--31)      0.386
  Medication                                                                                                                          
  L‐DOPA use, *n* (%)                     12 (100)               18 (100)             1           14 (100)           95 (97.9)        0.588
  L‐DOPA use, monotherapy, *n* (%)        1 (8.3)                5 (27.8)             0.192       1 (7.1)            19 (19.6)        0.257
  DA use, *n* (%)                         10 (83.3)              9 (50)               0.063       12 (85.7)          50 (51.5)        0.016
  Pramipexole IR use, *n* (%)             0                      2 (11.1)             0.232       1 (7.1)            3 (3.1)          0.447
  Pramipexole ER use, *n* (%)             1 (8.3)                3 (16.7)             0.511       2 (14.3)           12 (12.4)        0.840
  Ropinirole CR use, *n* (%)              3 (25)                 0 (0)                0.025       3 (21.4)           17 (17.5)        0.723
  Rotigotine use, *n* (%)                 1 (8.3)                2 (11.1)             0.804       4 (28.6)           11 (11.3)        0.078
  Pergolide use, *n* (%)                  6 (50)                 1 (5.6)              **0.005**   2 (14.3)           7 (7.2)          0.366
  Amantadine use, *n* (%)                 4 (33.3)               5 (27.8)             0.745       1 (7.4)            20 (20.6)        0.229
  Selegiline use, *n* (%)                 4 (33.3)               4 (22.2)             0.500       5 (35.7)           23 (23.7)        0.252
  Entacapone use, *n* (%)                 6 (50)                 5 (27.8)             0.216       4 (28.6)           14 (14.3)        0.180
  Zonisamide use, *n* (%)                 5 (41.7)               6 (33.3)             0.643       8 (57.1)           16 (16.5)        **\<0.001**
  Istradefylline use, *n* (%)             1 (8.3)                2 (11.1)             0.144       4 (28.6)           11 (11.3)        0.080
  LED‐total mg, median (IQR)              782.5 (593.8--1,060)   740 (612.5--918.8)   0.966       788 (598--1,156)   610 (500--850)   0.099
  LED‐L‐DOPA mg, median (IQR)             400 (300--625)         575 (450--600)       0.223       500 (363--588)     500 (300--600)   0.961
  LED‐DA mg, median (IQR)                 137.5 (125--245)       75 (0--275)          0.384       200 (150--300)     75 (0--280)      0.021
  LED‐other PD medication, median (IQR)   195 (0--231)           77.5 (0--169)        0.289       37.5 (0--165)      0 (0--150)       0.480
  ΔLED‐total mg, median (IQR)             70 (0--197.5)          70 (0--198)          0.896       12.5 (0--95)       100 (0--215)     0.183
  ΔLED‐L‐DOPA mg, median (IQR)            0 (0--100)             25 (0--150)          0.555       0 (0--150)         0 (0--150)       0.3
  ΔLED‐DA mg, median (IQR)                0 (0--46.3)            0 (0--0)             0.434       0 (0--28.8)        0 (0--5)         0.984

CR: controlled release; DA: dopamine agonist; ER: extended release; ICB: impulse control behavior; IQR: interquartile range; IR: immediate release; LED: L‐DOPA equivalent dose; RBD: rapid eye movement sleep behavior disorder.

Bold indicates *p* \<0.01.
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Patients without ICB at baseline but who developed it over the 2 years of follow‐up significantly more likely to be male (*p* = 0.009), and have more like to have dyskinesia (*p* = 0.006), and zonisamide use (*p* \< 0.001) than patients who had not developed ICB. Other variables did not differ between the two groups.

Punding and hobbyism were the most frequent ICBs, and no patient had symptoms of walkabout (Table [2](#brb31036-tbl-0002){ref-type="table"}). The types of ICB and the numbers of positive QUIP modules did not differ between ICB persister and ICB developer patients (Table [2](#brb31036-tbl-0002){ref-type="table"}).

Dose change medications during the 2‐year follow‐up are shown in Table [4](#brb31036-tbl-0004){ref-type="table"}. There were no differences in any aspects of PD medication between ICB persister and ICB remitter patients in the group with ICB at baseline. Of the group without ICB at baseline, 57.1% in the ICB developer group had DA treatment initiated or the dose increased, versus 28.9% of those without ICB. Rotigotine (*p* = 0.005), entacapone (*p* = 0.005), zonisamide (*p* \< 0.001), and istradefylline (*p* = 0.001) were initiated or doses increased more frequently in ICB developer than those without ICB (Table [4](#brb31036-tbl-0004){ref-type="table"}). Of the group without ICB at baseline, 64.3% had their DA discontinued, or dose reduced in ICB developer group versus 15.5% in patients without ICB (*p* \< 0.001) (Table [4](#brb31036-tbl-0004){ref-type="table"}). Pramipexole ER (*p* = 0.001) were discontinued or doses reduced more frequently in ICB developer than in patients without ICB (Table [4](#brb31036-tbl-0004){ref-type="table"}).

###### 

Dose changes to medications during the 2‐year follow‐up

                                                     ICB+ at baseline   ICB− at baseline                                  
  -------------------------------------------------- ------------------ ------------------ ------- ---------- ----------- -------------
  Initiated or dose increased medication, *n* (%)                                                                         
  L‐DOPA                                             3 (25)             9 (50)             0.171   7 (50)     36 (37.1)   0.355
  Dopamine agonist                                   3 (25)             4 (22.2)           0.860   8 (57.1)   28 (28.9)   0.035
  Pramipexole IR                                     0                  0                          0          1 (1.0)     0.703
  Pramipexole ER                                     0                  1 (5.6)            0.406   0          5 (5.2)     0.385
  Ropinirole CR                                      1 (8.3)            1 (5.6)            0.765   1 (7.1)    10 (10.3)   0.711
  Rotigotine                                         1 (8.3)            1 (5.6)            0.765   5 (35.7)   9 (9.3)     **0.005**
  Pergolide                                          1 (8.3)            1 (5.6)            0.765   2 (14.3)   3 (3.1)     0.059
  Amantadine                                         0                  1 (5.6)            0.406   0          7 (7.2)     0.299
  Selegiline                                         2 (16.7)           1 (5.6)            0.320   4 (28.6)   14 (14.4)   0.180
  Entacapone                                         4 (33.3)           2 (11.1)           0.136   5 (35.7)   9 (9.3)     **0.005**
  Zonisamide                                         3 (25)             4 (22.2)           0.860   6 (42.9)   9 (9.3)     **\<0.001**
  Istradefylline                                     1 (8.3)            2 (11.1)           0.804   5 (35.7)   7 (7.2)     **0.001**
  Droxidopa                                          0                  1 (5.6)            0.406   0          4 (4.1)     0.439
  Trihexyphenidyl                                    0                  0                  1       0          1 (1.0)     0.703
  Discontinued or dose reduced medication, *n* (%)                                                                        
  L‐DOPA                                             0                  0                          3 (21.4)   6 (6.2)     0.051
  Dopamine agonist                                   0                  0                          9 (64.3)   15 (15.5)   **\<0.001**
  Pramipexole IR                                     0                  2 (11.1)           0.232   0          0           
  Pramipexole ER                                     0                  0                          3 (21.4)   2 (2.1)     **0.001**
  Ropinirole CR                                      0                  0                          2 (14.3)   8 (8.2)     0.461
  Rotigotine                                         0                  0                          1 (7.1)    2 (2.1)     0.273
  Pergolide                                          0                  0                          1 (7.1)    2 (2.1)     0.273
  Amantadine                                         2 (16.7)           0                  0.073   3 (21.4)   5 (5.2)     0.028
  Selegiline                                         0                  1 (5.6)            0.406   0          1 (1.0)     0.703
  Entacapone                                         0                  1 (5.6)            0.406   0          3 (3.1)     0.505
  Zonisamide                                         0                  0                          1 (7.1)    3 (3.1)     0.447
  Istradefylline                                     1 (8.3)            0                  0.213   0          2 (2.1)     0.588

CR: controlled release; ER: extended release; ICB: impulse control behavior; IR: immediate release.

Bold indicates *p* \<0.01.
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4. DISCUSSION {#brb31036-sec-0012}
=============

We conducted longitudinal assessments of the remission, persistence and development of ICB, and the associated risk factors in a cohort study of over 140 PD patients. To our knowledge, this is the first report: (a) the ICB remission ratio using QUIP, (b) the potential association of ICB persistence with younger age and pergolide use, (c) the potential association of ICB development with zonisamide and istradefylline use, and (d) a longitudinal assessment from East Asia.

The ratio of ICB remission was 60% and that of development was 12.6% over the 2 years of our study. In previous studies, the ICB remission ratio in PD was found to range from 40% over a 3.5‐year follow‐up period by Siri et al. ([2015](#brb31036-bib-0038){ref-type="ref"}) in Italy, 58.1% over 12.1 months by Avila et al. ([2011](#brb31036-bib-0003){ref-type="ref"}) in Spain, 72.7% over 43.2 months by Sohtaoglu et al. ([2010](#brb31036-bib-0040){ref-type="ref"}) in Turkey to 73.3% over 29.2 months by Mamikonyan et al. ([2008](#brb31036-bib-0027){ref-type="ref"}) in the United States. Our remission ratio was similar to the report of Avila et al. ([2011](#brb31036-bib-0003){ref-type="ref"}), higher than that of Siri et al. ([2015](#brb31036-bib-0038){ref-type="ref"}), and lower than those of Sohtaoglu et al. ([2010](#brb31036-bib-0040){ref-type="ref"}) and Mamikonyan et al. ([2008](#brb31036-bib-0027){ref-type="ref"}). Although why the ICB remission ratio varies is very complex, we speculate that the differences may be explained by methodological factors, ethnic factors, environmental backgrounds, or the frequency of dopamine replacement therapy (DRT) (Chiang, Huang, Chen, & Wu, [2012](#brb31036-bib-0008){ref-type="ref"}; Tanaka et al., [2013](#brb31036-bib-0041){ref-type="ref"}).

Methodologically, other than the study of Siri et al. ([2015](#brb31036-bib-0038){ref-type="ref"}), no other previous studies and the current study investigated patients retrospectively. And the screening tools to detect ICB were different. ICB was assessed by the Minnesota Impulse Disorder Interview (MIDI) by Mamikonyan et al. ([2008](#brb31036-bib-0027){ref-type="ref"}). Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM‐IV) and criteria of their own by Sohtaoglu et al. ([2010](#brb31036-bib-0040){ref-type="ref"})), Voon and Fox\'s criteria by Avila et al. ([2011](#brb31036-bib-0003){ref-type="ref"}) and Siri et al. ([2015](#brb31036-bib-0038){ref-type="ref"}). The MIDI (Christenson et al., [1994](#brb31036-bib-0009){ref-type="ref"}) can be used to evaluate pathological gambling, sexual behavior, and compulsive buying; in addition to them, Voon and Fox\'s criteria include assessment of binge eating, punding, and DDS. The QUIP evaluates these ICB categories and is able to hobbyism and walkabout. Therefore, QUIP covers wider ICB categories than other criteria. The criteria with have narrower categories (MIDI, DSM‐IV) tend to reveal higher ICB remission ratios, whereas those of wider categories (Voon and Fox\'s criteria) seem to reveal lower ICB remission ratios than the current study. QUIP is becoming a standard screening tool to assess ICB in PD, which is used by Parkinson\'s Progression Markers Initiative (<http://www.ppmi-info.org/>) because it is comprehensive, self‐administered, and easy to complete (patients are able to complete the short form within 3 min) (Weintraub et al., [2009](#brb31036-bib-0050){ref-type="ref"}). It is also able to evaluate a wide range of ICB symptoms in one instrument. The disadvantage of QUIP is its low specificity but high sensitivity. In a direct comparison of QUIP and MIDI, the prevalence of ICB by QUIP has been 5% higher than MIDI (Antonini et al., [2017](#brb31036-bib-0001){ref-type="ref"}). Moreover, QUIP was positive in 20.3% in healthy subjects (Weintraub, Papay, & Siderowf, [2013](#brb31036-bib-0052){ref-type="ref"}). Therefore, to determine ICB diagnosis, other diagnostic criteria are needed. In our study, we adopted Voon and Fox\'s diagnostic criteria, when QUIP screening was positive.

In regard to ethnic factors, the ICD and ICB prevalences in Asian countries are relatively low by comparison with Western countries (Chiang et al., [2012](#brb31036-bib-0008){ref-type="ref"}; Tanaka et al., [2013](#brb31036-bib-0041){ref-type="ref"}; Wang, Wei, & Xiao, [2016](#brb31036-bib-0048){ref-type="ref"}). The prevalence of ICB in patients with PD using QUIP varies between 18.5% (Weintraub et al., [2013](#brb31036-bib-0052){ref-type="ref"}) to 58.3% (Vela et al., [2016](#brb31036-bib-0044){ref-type="ref"}) in Western countries, 35.0% in Malaysia (Lim et al., [2011](#brb31036-bib-0026){ref-type="ref"}), and 42.8% in India (Sharma et al., [2015](#brb31036-bib-0037){ref-type="ref"}). In our study, the prevalence of ICB at baseline was 21.3%, which is similar to a previous QUIP study in Japan (21.5%) (Tanaka et al., [2013](#brb31036-bib-0041){ref-type="ref"}). Medication practices, cost burdens, and health insurance have been suggested as potential factors with influencing the different prevalences (Fan et al., [2009](#brb31036-bib-0013){ref-type="ref"}). Genetic variants of serotonin receptors and polymorphisms for the dopaminergic, serotonergic, glutamate, and opioidergic systems have been related to the development of ICB in patients with PD (Comings & Blum, [2000](#brb31036-bib-0010){ref-type="ref"}; Ibanez, Blanco, Perez de Castro, Fernandez‐Piqueras, & Saiz‐Ruiz, [2003](#brb31036-bib-0018){ref-type="ref"}; Kraemmer et al., [2016](#brb31036-bib-0020){ref-type="ref"}; Le Foll, Gallo, Le Strat, Lu, & Gorwood, [2009](#brb31036-bib-0022){ref-type="ref"}; Lee, Jeon, Kim, & Park, [2012](#brb31036-bib-0023){ref-type="ref"}; Lee et al., [2009](#brb31036-bib-0024){ref-type="ref"}; Zainal Abidin et al., [2015](#brb31036-bib-0055){ref-type="ref"}). Thus, genetic variations in receptors, transporters, or enzymes of the catecholaminergic, serotonergic, glutamatergic, and opioid neurotransmission systems are potentially associated with ICD in PD (Jimenez‐Urbieta et al., [2015](#brb31036-bib-0019){ref-type="ref"}).

To consider environmental backgrounds, accessibility to gambling differs among countries, and casinos are not present in Japan. Hobbyism was the most frequent ICB symptom in our cohorts. The technological opportunities available to Japanese people today may lead to high rates of hobbyism (e.g., playing smartphone games or spending more time on the Internet, on surfing or on social networking services). We speculate that this could influence the prevalence of ICBs especially in younger patients.

Dopamine agonist was used by 46.8% of patients in our study (Table [1](#brb31036-tbl-0001){ref-type="table"}), which is relatively lower than the previous QUIP study in Japan (56%) (Tanaka et al., [2013](#brb31036-bib-0041){ref-type="ref"}). Proposed treatment strategies from the "Treatment Guideline for PD 2011" by the Japanese Society of Neurology (<https://neurology-jp.org/guidelinem/parkinson.html>) recommend that DA be the first‐line therapy for patient under 70 years old unless special circumstances indicate the prioritization of immediate improvement of symptoms. Our cohort had a relatively higher age of disease onset than the previous study (Tanaka et al., [2013](#brb31036-bib-0041){ref-type="ref"}). Therefore, DA might be used less in our cohort than in the previous study.

At baseline, pergolide use was significantly higher in patients with ICB than in patients without ICB. Pergolide use has been reported to be a risk factor for the development of ICB (Weintraub et al., [2006](#brb31036-bib-0053){ref-type="ref"}), and findings are consistent with this.

At 2‐year follow‐up, significantly more patients in the group with ICB at baseline had ICB than the group without ICB at baseline. Overall, patients in the ICB persister group were younger, pergolide use than ICB remitters. Younger age and pergolide use have been reported to be risk factors for the development of ICB (Antonini et al., [2017](#brb31036-bib-0001){ref-type="ref"}; Weintraub et al., [2006](#brb31036-bib-0053){ref-type="ref"}, [2015](#brb31036-bib-0049){ref-type="ref"}; Zurowski & O\'Brien, [2015](#brb31036-bib-0056){ref-type="ref"}). Our findings suggest that these factors may also be related to the persistence of ICB.

D3 receptors may be involved in the pathogenesis of ICB. DAs with preferential affinity for the D3 receptor have strong association with ICB (Moore, Glenmullen, & Mattison, [2014](#brb31036-bib-0029){ref-type="ref"}). Pergolide has D3 receptor affinity (Kvernmo, Hartter, & Burger, [2006](#brb31036-bib-0021){ref-type="ref"}), and its use has been reported to be risk factors for the development of ICB (Weintraub et al., [2006](#brb31036-bib-0053){ref-type="ref"}). Consequently, pergolide might be associated with ICB persistence followed by ICB development. Ergot‐DAs are typically not the first choice of DA because they are risk factors for adverse cardiac valve regurgitation (Schade, Andersohn, Suissa, Haverkamp, & Garbe, [2007](#brb31036-bib-0036){ref-type="ref"}). However, Japanese drug information sheets on non‐ergot DAs have physicians instruct the patient not to drive while taking non‐ergot DAs. Accordingly, ergot‐DAs, such as pergolide, may sometimes be the first choice in patients with PD who want to drive. Our region is a relatively rural area in Japan with poor public transportation. ICB persisters were younger than ICB remitters (Table [3](#brb31036-tbl-0003){ref-type="table"}); hence, active drivers are more likely to be included in the ICB persister group. Consequently, pergolide might tend to be the medication of choice in younger patients.

The factors previously reported to be associated with ICB remission were reduction in DA use (Avila et al., [2011](#brb31036-bib-0003){ref-type="ref"}) and lower DA dosage (Mamikonyan et al., [2008](#brb31036-bib-0027){ref-type="ref"}; Sohtaoglu et al., [2010](#brb31036-bib-0040){ref-type="ref"}). However, our data did not show any differences in ΔLED‐DA and drug prescription between the ICB persister and ICB remitter groups (Tables [3](#brb31036-tbl-0003){ref-type="table"} and [4](#brb31036-tbl-0004){ref-type="table"}). Younger age and pergolide use may potentially be new factors associated with ICB persistence.

The patients who developed ICB in the group of ICB negative at baseline were more often male, and had dyskinesia and zonisamide than patients without ICB. Being male has been reported as a risk factor for the development of ICB (Antonini et al., [2017](#brb31036-bib-0001){ref-type="ref"}; Weintraub, Koester, et al., [2010](#brb31036-bib-0051){ref-type="ref"}; Weintraub, et al., [2015](#brb31036-bib-0049){ref-type="ref"}; Zurowski & O\'Brien, [2015](#brb31036-bib-0056){ref-type="ref"}). Both L‐DOPA induced dyskinesia (LID), and ICB can be induced by excessive dopaminergic stimulation in the motor or limbic territories of the striatum (Jimenez‐Urbieta et al., [2015](#brb31036-bib-0019){ref-type="ref"}; Rocha, Gago, Barbosa, Cavaleiro, & Laranjinha, [2015](#brb31036-bib-0033){ref-type="ref"}). Biundo et al. have reported in ALTHEA study, more than half of PD patients with dyskinesia also had ICB. In addition, patients with moderate‐to‐severe dyskinesia had ICB more frequently than patients with only mild dyskinesia (Biundo et al., [2017](#brb31036-bib-0005){ref-type="ref"}). DA use and high doses of DA have previously been shown to increase the risk of ICB development (Moore, Glenmullen, et al., [2014](#brb31036-bib-0029){ref-type="ref"}; Weintraub, Koester, et al., [2010](#brb31036-bib-0051){ref-type="ref"}).

Zonisamide, which is approved as an antiepileptic agent throughout the world, has not been reported as a risk factor for ICB. In 2009, zonisamide was approved for the treatment of PD in Japan. The precise sites of action have remained largely unknown, but zonisamide has multiple actions, including inhibition of sodium channels, T‐type calcium channels, monoamine oxidase‐B activity, activation of dopamine synthesis, and dopamine release (Murata et al., [2015](#brb31036-bib-0031){ref-type="ref"}). In a recent study, zonisamide enhanced novelty‐seeking behavior in rats (Uemura, Asano, Hikawa, Yamakado, & Takahashi, [2017](#brb31036-bib-0043){ref-type="ref"}). Higher novelty‐seeking traits are known to indicate a greater risk for ICB (Voon et al., [2011](#brb31036-bib-0047){ref-type="ref"}). Therefore, we believe that the dopaminergic actions and novelty‐seeking enhancement of zonisamide might be related to the development of ICB in PD.

During the 2‐year follow‐up, rotigotine, entacapone, zonisamide, and istradefylline treatments were significantly more likely to be initiated, or doses increased, in ICB developers than in patients without ICB (Table [4](#brb31036-tbl-0004){ref-type="table"}). Although rotigotine has been reported to confer a lower risk compared with other DAs (Garcia‐Ruiz et al., [2014](#brb31036-bib-0015){ref-type="ref"}; Moore, Khalaj, et al., [2014](#brb31036-bib-0030){ref-type="ref"}; Rizos et al., [2016](#brb31036-bib-0032){ref-type="ref"}), rotigotine has D3 receptor affinity, and furthermore, in a post hoc analysis of six open‐label extension studies, 71 of 786 patients (9%) with rotigotine treatment developed ICB (Antonini et al., [2016](#brb31036-bib-0002){ref-type="ref"}). Hence, rotigotine could be a risk factor for the development of ICB. An association between entacapone and ICB has not been reported to date. Entacapone, a catechol‐O‐methyltransferase (COMT) inhibitor, reduces peripheral catabolism of L‐DOPA and improves its effective delivery to the brain, and has subsequent clinical effects, in PD patients with motor fluctuations (Lees, [2008](#brb31036-bib-0025){ref-type="ref"}). Concurrent use of L‐DOPA and DAs, and high dose of L‐DOPA have been linked to ICB such as DDS (Voon et al., [2011](#brb31036-bib-0047){ref-type="ref"}; Weintraub et al., [2015](#brb31036-bib-0049){ref-type="ref"}). Changes in COMT expression have also been associated with impulsivity (Vevera et al., [2009](#brb31036-bib-0045){ref-type="ref"}). Therefore, we speculate that entacapone seems to be involved in the development of ICB.

The association between istradefylline and ICB has not been reported. Istradefylline, a selective adenosine A~2A~ receptor antagonist, has nondopaminergic effects because it lacks effects on dopamine receptors and dopamine‐metabolizing enzymes (Mizuno & Kondo, [2013](#brb31036-bib-0028){ref-type="ref"}). Istradefylline improves motor function, without worsening LID, in animal models. A clinical trial has shown that istradefylline is effective in improving motor symptoms in PD patients (Mizuno & Kondo, [2013](#brb31036-bib-0028){ref-type="ref"}) and it was approved for the treatment of wearing off under L‐DOPA co‐administration in PD patients in Japan in 2013. Adenosine A~2A~ receptors are abundant in the striatum and other nuclei of the basal ganglia, as well as in the nucleus accumbens (Rosin, Hettinger, Lee, & Linden, [2003](#brb31036-bib-0035){ref-type="ref"}), which plays a key role in the development of DDS (Evans et al., [2006](#brb31036-bib-0012){ref-type="ref"}), and adenosine A~2A~ receptors modulate the reward and reinforcement pathways (Filip, Zaniewska, Frankowska, Wydra, & Fuxe, [2012](#brb31036-bib-0014){ref-type="ref"}). Therefore, we hypothesize that the adenosine A~2A~ receptor antagonist istradefylline could cause excitatory stimulation in the mesolimbic area, leading to the development of ICB.

Entacapone monotherapy became available in Japan from December 2015. Until then, entacapone had been used in combination with DRT, with zonisamide and istradefylline only available with DRT at the current time. Therefore, entacapone treatment may tend to be initiated earlier than zonisamide and istradefylline. In addition, DRT use tends to be difficult in patients with ICB, and consequently, in our practice nondopaminergic drugs, such as zonisamide and istradefylline, tend to be used in patients with ICB. Further investigation is needed to confirm the association between ICB and entacapone, zonisamide, and istradefylline.

In the group without ICB at baseline, pramipexole ER were more frequently discontinued or the dose reduced in ICB developers than in patients who had not developed ICB during the 2‐year follow‐up. Two of the three patients in the ICB developer group had reduced their doses of pramipexole ER to mitigate ICB, so the reduction in pramipexole ER seems to be a result of the development of ICB rather than the cause.

There are some limitations of this study. First, this was a retrospective observational study, so our conclusions about the factors associated with the development of ICB may be tenuous. Second, the QUIP assessment was conducted by the patients or their caregivers and has some delicate questions, such as regarding sexual activity, so they may feel uncomfortable completing it honestly (Zurowski & O\'Brien, [2015](#brb31036-bib-0056){ref-type="ref"}). Some people feel ashamed or embarrassed about these behaviors and would not broach the subject by direct screening. Therefore, the prevalence of ICB in our study may underestimate the actual prevalence. Third, we were not able to conduct multivariate analyses with respect to the associated factors due to the small number of patients. Finally, this study was conducted in a single center and our patients may not represent the general PD population and the selection bias was not removed in each group. Prospective and larger sized studies are needed to confirm the association between ICB persistence or development and associated factors.

5. CONCLUSIONS {#brb31036-sec-0013}
==============

This study suggests that younger age and pergolide use may be potential new factors associated with ICB persistence, and further, entacapone, zonisamide, and istradefylline may be new factors associated with the development of ICB. Drug profiles and medication practices in Japan may explain the association of these factors with ICB. Physicians should pay careful attention to these potential factors when treating patients with PD to help avoid the development or persistence of ICB.
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